ABSTRACT The dynamic, innovative temperament of Christian Gespach is ideally suited to unraveling some aspects of the complex molecular networks connected with signal transduction, cancer progression and treatment. He is one of the pioneers who opened, in the early 1980s, new insights into the signaling mechanisms of G-protein coupled receptor (GPCR) activation, desensitization, internalisation and crosstalks. Twenty five years later and in collaboration with Gespach, IPSEN pharmaceuticals designed pan-inhibitors of GPCR signaling, targeting Ga subunits in breast cancer progression and other epithelial cancers. Creativity is of vital importance to understand signal transduction pathways engaged in cancer cell motility, invasion and drug resistance. Christian Gespach has published more than 200 papers in cancer research, a true signal transduction tale.
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Christian Gespach started his lifetime dedication to Science and Medical Research as a Pierre and Marie Curie student in 1967 (University Paris VI, France). During University training he worked in a full time position at the French National Education Colleges in Paris and Créteil Academy (1968-1976) . �e su�se�uently per�e su�se�uently performed his graduate studies in �ospital Saint-Antoine (INSERM U55 la�oratory), where he was involved in projects aiming at elucidating the role of glucose, incretins and neuropeptides in the �iosynthesis and secretion of pancreatic hormones (1975) (1976) (1977) . As a PhD graduate, he joined the la�oratory of Dr. Jean-Pierre A�ita at INSERM U204 (1979-1987) , �ospital Saint-Louis (signal transduction in normal and leukemic hematopoietic cells) to work on histamine �2 receptors, neutrophil chemotaxis and differentiation of leukemic cells �y retinoic acid, vitamine D3 and �ile acids (Zim�er et al., 2000) . In 1979, he o�tained a staff position at INSERM in Paris, where he continued to work on signal transduction in normal and cancerous digestive epithelial cells and leukemic cells (State Doctorate in Sciences, 1986) .
My first contact with Christian Gespach was via a telephone conference in 2001. During this period, we had several interactions concerning the role of myofibroblasts in colon cancer invasion. Proof of the fruitful discussions was the pu�lication of the work in FASEB Journal and Journal of Cell Science (De Wever et al., 2004a . After my PhD in 2004, I was fortunate to organize multiple long term and short term yearly visits to the Gespach la�. Paris is only 300 km away from Ghent and luckily we have a direct fast train connection. A two hour trip �rings you from Ghent in Paris Nord train station. My first stay covered a�out 8 weeks in late May till early July of 2004. I stayed in a pictures�ue house in Périgny-sur-Yerres, a su�ur� 25 km to the south of Paris. One of the crazy experiments during those days was a �icycle trip during rush hour from Périgny to the host la�, located in the center of Paris. The Gespach lab had a driving scientific atmosphere with multiple successful young la� mem�ers such as Samir Attou�, Quang-Dé Nguyen, Sylvie Rodrigues, Nathalie Le Floch, Christelle Rodrigue and Christine Rivat. I was honoured to perform experiments with so many creative minds educated �y Christian Gespach. This visit formed a solid �asis for multiple future pu�lications and colla�orative efforts.
In Decem�er, 2010 Christian Gespach was invited to the Ghent la�oratory of Experimental Cancer Research to discuss recent colla�orative data. The day started with discussing a future strategy a�out the NM23 metastasis suppressor. This project was engaged under mutual interactions with Dr. Mathieu Boissan and Dr. MarieLise Lacom�e in �ospital Saint-Antoine, INSERM U938 showing that the metastasis suppressor NM23�1 is involved in the maintenance of E-cadherin-�ased adherens junctions and control of epithelial cancer cell scattering and adhesion in primary tumors (Boissan et al., 2010) . We continued the discussion a�out the cross-signaling �etween �one marrow-derived mesenchymal stem cells and colon cancer cells. Only at the end of the day I managed to s�ueeze in a few of my �uestions! Rodbell and Alfred Gilman (Nobel prize laureates, 1994) . Both heterotrimeric G-proteins (hGP) (Gas, Gaolf, Gai) , Gbg) , Gaq) , PLCb and PKC (Gaq, Ga12/13, Gbg) 
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Upon interaction and activation by a given selective ligand agonist, G-protein coupled receptors (GPCR) promote GPCR-hGP interaction and the GDP /GTP exchange at Ga subunits through G-protein exchange factors GEFs, leading to decreased affinity of Ga-GTP for Gbg and promoting their dissociation. Then, activated Ga-subunits, Gbg dimers, Ga-and Gb monomers activate several downstream signaling elements and effectors such as adenylyl cyclases
, ions channels (Gbg), and transactivate tyrosine kinase receptors (HER1 and Gb for example). GPCR signals mediated by hGP are interrupted or reinitialized by several mechanisms including: i) GPCR phosphorylation by GPCR kinases; ii) Receptor internalization, degradation or recycling; iii) The regulators of G-protein signaling (RGS) working as Ga-GTPase activators; iv) Reassociation of latent Ga-GDP/Gbg heterotrimers.
Did your family have a strong scientific tradition?
My family was not involved in practical or experimental medicine �ut was mainly working in accounting expertise and commercial �anking.
When did you enter into the field of cell signaling?
I was scientifically born as a researcher in the laboratory of Dr. Ga�riel Rosselin (INSERM U55) working on Dia�etes and Digestive Diseases (mem�rane receptors, signal transduction and cyclic nucleotides cAMP /cGMP).
Christian Gespach is one of the pioneers who opened, in the early 1980s, new insights in the signaling mechanisms of Gprotein coupled receptors (GPCRs) activation, desensitization, internalisation and crosstalks (VIP and histamine �2 receptor regulation �y somatostatin).
As shown in Fig. 1 , the G-proteins Ga and Gbg signaling systems downstream GPCR cycle �etween ligand activated Ga-GTP + Gbg su�units and return to the Ga-GDP /Gbg heterotrimeric, inactivated state. The GTP-�ound activated state of Ga proteins can be mimicked by aluminium fluoride (AlF4-) and the nonhydrolyza�le GTP analogues GTP-gS and GDP-N�P (Fig. 2) .
Relations of GPCR signaling with oncogenic pathways and functional defects associated with the progression of epithelial cancers were analyzed �y Gespach et al., in normal, immortalized and transformed epithelial cells of the colon, stomach and �reast (Gespach et al., 1980 , Gespach et al., 1981a , Gespach et al., 1981b . Twenty five years later and in collaboration with Gespach, IPSEN pharmaceuticals designed pan-inhi�itors of GPCR signaling targeting Ga su�units in the MCF-7 �reast cancer cell line and the invasive growth of epithelial cancer cells and tumors (Ayou� et al., 2009 , Prevost et al., 2006 (Fig. 3) . Many GPRC signals are connected with critical dysfunctions inherent to leukocyte and epithelial cell chemotaxis and oncogenesis. First attempts to control cancer progression �y targeting a given GPCR were unsuccessful �ecause of the multifactorial nature and partial redundancy of the genetic and molecular defects driving neoplasia. Recently, the therapeutic anti-cancer potential of these small molecule signaling inhi�itors downstream GPCR has �een documented �y other groups targeting Gbg su�units. GPCR and their signal transduction systems are involved in normal development, various physiopathological states and are now considered as canonical oncogenic pathways in �reast cancers and clinical tumors (Fig. 4) . At the end of the nineties, Gespach la�oratories have made significant advances in molecular and clinical oncology of epithelial tumors in �reast, gastrointestinal tract and urogenital systems. For example, Dr. Gespach contri�uted to the elucidation of several mechanisms involved in gene expression (TCF/LEF1-b-catenin and c-Jun/AP-1 synergy, STAT-3 signaling), cancer cell differentiation, invasive growth, tumor angiogenesis, metastasis and chemoresistance. This was accomplished at the level of the retino�lastoma proteins pR�1 and pR�2, src, Wnt receptors Frizzled, CXCR4 /MIF axis, throm�in PAR-1 and their signaling commutators (RhoA/ RhoD, the NO/ cGMP axis), the Gep oncogenes Ga12/13, the Gai su�units family including the and Gip2 oncogene Gai2, Gbg and Gaolf). The INSERM U482 and U673 Teams (Fig. 5) contri�uted to major advances on oncogenic pathways controlled �y receptor and nonreceptor tyrosine and serine/threonine kinases TGFb, PKCa, c-kit, leptin, VEGF/ semaphorin family and neurotensin), Rho-like small GTPases, trefoil factors family TFF and their connections with src and EGFR, netrin and deleted in colon cancer (DCC dependance receptor and adenosine A2� co-receptor), and functional responses to the estrogen receptor a (ERa)-dependent nuclear transcription factor and repressor WISP-2 and its implication in epithelialmesenchymal transition (EMT). A significant account of research directed by Gespach was focused on immortalization and transformation of human colon and �reast and epithelial cells in order to mimick and characterize genetic, molecular and functional mechanisms at the adenoma-adenoma transition: SV40 Large T, Adenovirus 2 E1A, Ras /TGFb, Src and Polyoma middle T oncogenes (Berthon et al., 1992 , Chastre et al., 1991 , Emami et al., 1989 , Empereur et al., 1997 . This strategy was also applied to other genetic diseases such as Myasthenia gravis and Cystic Fi�rosis (Chastre et al., 1991 , Lemnaouar et al., 1993 , Marie et al., 1999 . Preclinical studies supporting the therapeutic role of signalPreclinical studies supporting the therapeutic role of signaling inhi�itors and oxaliplatin com�ined with 5-FU and folinic acid /leucovorin or irinotecan were the �asis of current chemotherapy in colorectal cancer, the FOLFOX and FOLFIRI regimens (Andre et al., 2004 , Raymond et al., 1997 . INSERM U482 was the first la�oratory to clone the alternative spliced form of Rac1 encoding the constitutively activated form of this GTPase named Rac1� (Jordan et al., 1999) . This important discovery was �ased on the novel hypothesis of Dr. Gespach that molecular alterations might target the Rho-like small GTPases, as descri�ed for Ki-ras mutations in a vast majority of epithelial cancers. The hype started in 2005 when the Bissell group pu�lished in Nature a crucial role of Rac1� in matrix metalloproteinase-3 induced EMT and invasion in �reast cancer cells (Radisky et al., 2005) . As recently reviewed �y C. Gespach, clinical �reast cancers and several malignant epithelial tumors display EMT signatures and markers with prognosis significance for recurrence, metastasis, overall survival and therapeutic resistances (Sa��ah et al., 2008) . Christian Gespach was invited as speaker and chairman in more than 40 international meetings, conferences and seminars in Europe, USA, Canada, Venezuela, United Ara� Emirates, China and Japan (Fig. 6 ).
Tumors and their metastatic niches are complex organs consisting of genetically reprogrammed cancer cells and the tumor stroma (from Greek translated as "bed"). This tumor stroma is also reciprocally "transformed" by cancer cells and consists of complex networks of extracellular matrix (ECM) molecules involved at several interfaces with fibroblasts, adipocytes, mesenchymal stem cells, the vascular and immune systems. Tumor-associated fibroblasts that express a-smooth muscle actin are referred to as myofibroblasts. Myofibroblasts are factories producing multiple growth factors, ECM proteins and proteases to support cancer invasion. Where do we stand today with the clinical applications of this concept?
Several signals from the literature highlight the critical importance of the molecular and cellular crosstalks �etween cancer cells and their immediate and distant environment, respectively the tumor stroma, mesenchymal stem cells in �one marrow and other tissues, and also from metastatic sites, according to the self-seeding and trafficking theory of the Massague and Weinberg groups (reviewed in Gespach, 2010) . It is therefore apparent that the cancer cell-stroma connections are invoved in several steps of the neoplastic conversion, including cancer initiation, promotion and progression. Thus, the response of a given malignant tumor to chemotherapy and radiation should �e considered in view of the respective roles and sensitivity of these compartments to a given treatment. Drug resistances and cancer cell survival mechanisms originate from these �uestions. A �etter knowledge of these mechanisms and therapeutic disruption of their fatal conse�uence appears to �e one of the major challenges for the next 10 years.
A recent Pubmed search revealed less than 400 citations for Rab and cancer. Although belonging to the Ras family of small GTPases, RabGTPases are unexpected players in the cancer signaling field? This contrasts starkly with the founding members of the Ras superfamily small GTPases (H-Ras, Ki-Ras and N-Ras) which are prototypic oncogenes with more than 20.000 hits in Pubmed. I think that it is not surprising that regulated secretory Ra�-GTPases are involved in cancer progression �ecause released products from cancer cells and tumor stroma cells are playing major roles on autocrine, juxtacrine and paracrine regulations and transforming functions in cancer cells, adjacent tumor stroma cells, and systemic regulations of distant metastasis �y cancer cell homing and growth. We have greatly contri�uted to this concept to identify critical secreted factors from cancer cells and tumor stromal cells �y using conditioned culture medium and co-culture systems . stitutions, will offer a comprehensive project to promote significant advances in this field. (Emami et al., 2001) . This pu�lication was the leading discovery of several reports from our la�oratory and several international research institutions on the transforming roles of trefoil factors (TFFs) in epithelial cancers. I think that this report opened new avenues for cancer research and treatment (reviewed in (Emami et al., 2004) . Most importanly, Gespach clarified the dual roles of TFFs and their therapeutic potential on wound healing, mucosal repair, transient inflammatory situations and tumorigenesis. In the stomach, TFF1 is bona fide a gastric tumor suppressor gene lost �y epigenetic silencing. Consistently, TFF1 /pS2 is a limiting factor against the erosion of the gastric epithelial cell surface and counteracts inflammatory situations and cancer promotion. In contrast, in the mucosa of the lower digestive tract and colon, TFFs are found to �e overexpressed and display pejorative functions during these chronic pathological states. In �reast cancer, TFF1 expression is linked to a favora�le prognosis for patient survival, but this beneficial situation is linked to the differentiated -type, ER-a -positive state of �reast cancers that have a favora�le prognosis �ecause of their sensitivity to classical, efficient targeted hormone therapy (reviewed in Gespach, 2008) .
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